1862-8354/asset/olbannerleft.jpg?v=1&s=47a2691c51f9d6e6d83bcad52a29869e7c0a62ec)
Viewpoint
Biomarkers as disease definition: Mantle cell lymphoma as an example
Article first published online: 22 NOV 2010
DOI: 10.1002/prca.201000048
Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Issue
PROTEOMICS - Clinical Applications
Special Issue: Focus on Pathways to Translation of Proteomics into Clinical Practice
Volume 4, Issue 12, pages 922–925, December 2010
Additional Information
How to Cite
van Krieken, J. H. J. M., Jansen, C., Hebeda, K. M. and Groenen, P. J. T. A. (2010), Biomarkers as disease definition: Mantle cell lymphoma as an example. Prot. Clin. Appl., 4: 922–925. doi: 10.1002/prca.201000048
Publication History
- Issue published online: 29 NOV 2010
- Article first published online: 22 NOV 2010
- Accepted manuscript online: 3 NOV 2010 02:55AM EST
- Manuscript Accepted: 23 AUG 2010
- Manuscript Received: 7 JUN 2010
- Abstract
- Article
- References
- Cited By
Keywords:
- Biomarker;
- Malignant lymphoma;
- Mantle cell lymphoma;
- Pathology
Abstract
The introduction in pathology practice of a new biomarker that is contributing to define a disease requires a series of investigations. Now that new biomarkers are being discovered continuously it is important to learn from successful examples of markers that are presently widely used. In this historical account the steps are described that have led to the use of immunohistochemical staining of tissue samples with an antibody against cyclinD1 to diagnose mantle cell lymphoma. Furthermore, a short outlook is given on the introduction of proteomics as a tool in the diagnosis of lymphoma and the potential route to be taken for introducing this technology into clinical practice.